Nicotine

Generic Name: Nicotine

Brand Names: Habitrol, Nicoderm C-Q, Nicorelief, Nicorette, Nicotrol

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₄N_₂

CAS Number: 54-11-5

Unique Ingredient Identifier: 6M3C89ZY6R

Background: Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke.

Indication: For the relief of nicotine withdrawal symptoms and as an aid to smoking cessation.

Associated Conditions: Withdrawal Nicotine

Associated Therapies: Smoking cessation therapy

Clinical Trials

Group Therapy for Nicotine Dependence: Mindfulness and Smoking

Not Applicable

Completed

Conditions: Smoking
Tobacco Use Cessation

Interventions: Behavioral: MBAT Group Therapy
Drug: Nicotine
Behavioral: Group Therapy
Behavioral: Individual Therapy

First Posted Date: 2006-02-28

Last Posted Date: 2020-06-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 650

Registration Number: NCT00297479

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma

Phase 2

Completed

Conditions: Sarcoma

First Posted Date: 2006-02-24

Last Posted Date: 2013-06-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00295984

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Adjustment of DOses of NIcotine in Smoking Cessation (ADONIS)

Phase 4

Completed

Conditions: Smoking Cessation

Interventions: Procedure: Dose adjustment of nicotine replacement therapies
Drug: nicotine patch

First Posted Date: 2005-10-10

Last Posted Date: 2008-04-01

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 300

Registration Number: NCT00235313

Locations: 🇫🇷
Groupe Hospitalier Pitié-Salpétrière, Unité de Recherche Clinique, Paris, France

Computer-Assisted Scheduling of Nicotine Inhaler Use in Participants Who Plan to Stop Smoking

Not Applicable

Completed

Conditions: Head and Neck Cancer
Lung Cancer
Esophageal Cancer

First Posted Date: 2004-03-19

Last Posted Date: 2013-05-15

Lead Sponsor: Personal Improvement Computer Systems

Registration Number: NCT00021138

Locations: 🇺🇸
Personal Improvement Computer Systems, Incorporated, Reston, Virginia, United States

Comparison of Nicotine Inhaler and/or Bupropion in Helping People to Stop Smoking and Prevent the Recurrence of Smoking

Phase 3

Completed

Conditions: Lung Cancer

Interventions: Drug: bupropion hydrochloride
Drug: nicotine
Other: placebo

First Posted Date: 2004-02-06

Last Posted Date: 2016-07-13

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 1708

Registration Number: NCT00033592

Locations: 🇺🇸
Cancer Center of Kansas - Wichita, Wichita, Kansas, United States
🇺🇸
CCOP - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸
CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States

and more 22 locations

Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

Not Applicable

Completed

Conditions: Colorectal Cancer
Bladder Cancer
Breast Cancer
Head and Neck Cancer
Tobacco Use Disorder
Unspecified Adult Solid Tumor, Protocol Specific
Lung Cancer
Lymphoma
Prostate Cancer
Testicular Germ Cell Tumor

Interventions: Drug: nicotine
Behavioral: Usual Care

First Posted Date: 2003-08-11

Last Posted Date: 2023-06-15

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 434

Registration Number: NCT00002520

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Tobacco Cessation in Postmenopausal Women (Part II) - 2

Phase 1

Completed

Conditions: Tobacco Use Disorder

First Posted Date: 2003-05-22

Last Posted Date: 2015-12-02

Lead Sponsor: University of Minnesota

Target Recruit Count: 1

Registration Number: NCT00061074

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery

Phase 3

Terminated

Conditions: Lung Cancer

Interventions: Behavioral: smoking cessation intervention
Drug: bupropion hydrochloride
Procedure: psychosocial assessment and care
Drug: nicotine

First Posted Date: 2003-01-27

Last Posted Date: 2013-03-11

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 10

Registration Number: NCT00032084

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

and more 173 locations

5HT3 Antagonism and Auditory Gating in Schizophrenia

Not Applicable

Completed

Conditions: Schizophrenia

First Posted Date: 2001-07-05

Last Posted Date: 2009-01-21

Lead Sponsor: US Department of Veterans Affairs

Registration Number: NCT00018850

Locations: 🇺🇸
VAMC, Denver, Colorado, United States

Behavioral Economics of Human Drug Self-Administration

Completed

Conditions: Drug Dependence

First Posted Date: 2000-06-02

Last Posted Date: 2005-06-24

Lead Sponsor: National Center for Research Resources (NCRR)

Registration Number: NCT00005765

Locations: 🇺🇸
University of Vermont, Burlington, Vermont, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy